June 18, 2020 / 3:15 AM / 22 days ago

BRIEF-Protagonist Therapeutics says Hepcidin Mimetic PTG-300 Receives U.S. FDA Orphan Drug Designation

June 17 (Reuters) - Protagonist Therapeutics Inc:

* HEPCIDIN MIMETIC PTG-300 RECEIVES U.S. FDA ORPHAN DRUG DESIGNATION FOR THE TREATMENT OF POLYCYTHEMIA VERA Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below